Are you using TCRs to target solid tumors yet?

With Immunocore having achieved commercialization for the first TCR therapy and Adaptimmune hot on their tail, 2022 is fast becoming the year for TCRs.

Join the TCR-based Therapies for Solid Tumors Summit (June 27-29) to gain knowledge to accelerate the clinical development and improve the safety of these game-changing cell therapies.

Featuring 24+ expert speakers, over 80% of whom are new for 2022, this summit will address the toughest challenges in TCR development, such as improving TCR discovery and efficacy, combating the tumor microenvironment, optimizing target selection and advancing manufacturing, preclinical and clinical processes.

Join leaders in the field, including Adaptimmune, Iovance and TScan as they examine methods to prevent cross reactivity, increase cell fitness and infiltration, improve therapy safety and ultimately overcome the hurdles holding back these game-changing treatments from patients in need.

Find out more in the Event Guide: https://ter.li/sa0pnw